{"id":47986,"date":"2022-09-06T08:01:47","date_gmt":"2022-09-06T06:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/"},"modified":"2022-09-06T08:01:47","modified_gmt":"2022-09-06T06:01:47","slug":"frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/","title":{"rendered":"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nFormer Chief Financial Officer in numerous mid-caps and large international groups, with over 20 years\u2019 professional experience in France and abroad.\n<\/li>\n<li>\nThe expertise necessary to accelerate Valbiotis\u2019 future hypergrowth in charge of the global financial strategy.\n<\/li>\n<li>\nA new appointment at a milestone in the Company\u2019s history, in preparation for commercialization.\n<\/li>\n<\/ul>\n<p>LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/5\/LOGO-NOIR.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg\"><\/a><\/p>\n<p>\nValbiotis (FR0013254851 &#8211; ALVAL, PEA\/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the appointment of Fr\u00e9d\u00e9ric PELONG to the Company\u2019s Board of Directors.\n<\/p>\n<p>\nFr\u00e9d\u00e9ric PELONG joined Valbiotis on June 1 as Chief Financial Officer to support the Company\u2019s expansion. His arrival comes at a key moment in Valbiotis\u2019 history as it approaches its commercialization phase, with the upcoming market release of TOTUM\u202263 as part of a strategic partnership with Nestl\u00e9 Health Science and of TOTUM\u202270, expected no later than the first half of 2024.\n<\/p>\n<p>\nFr\u00e9d\u00e9ric PELONG aged 48, brings a wealth of experience in finance, acquired over more than twenty years working for mid-caps and major international groups managing high-profile brands. Former Financial Audit Manager at E&amp;Y, Fr\u00e9d\u00e9ric PELONG then held various cross-functional financial positions at Pernod Ricard before becoming Chief Financial Officer of the Swiss subsidiary. He was subsequently appointed Chief Financial Officer of the Christofle Group, and more recently Audika. Over his career, he has acquired a solid expertise in supporting growth and development in new markets, mastering a wide variety of business models. Fr\u00e9d\u00e9ric PELONG is a graduate of Kedge and holds a DECF accounting and financial diploma.\n<\/p>\n<p>\nFr\u00e9d\u00e9ric PELONG, Chief Financial Officer and member of the Valbiotis Board of Directors, comments: \u201c<i>Having started out working for various large groups, I\u2019m delighted to be embarking on the Valbiotis adventure. Valbiotis is a company that holds great potential and is entering a pivotal phase in its history, with the imminent marketing of products with scientifically proven efficacy. I\u2019m particularly pleased to have the opportunity to use my expertise to spur these developments because the Company\u2019s mission, which is to prevent metabolic and cardiovascular disease through the use of plant-derived active substances, is in line with my personal beliefs about what the medicine of tomorrow should look like<\/i>\u201d.\n<\/p>\n<p>\nS\u00e9bastien PELTIER, Chairman of the Board of Directors at Valbiotis, says: \u201c<i>Fr\u00e9d\u00e9ric\u2019s solid financial expertise and impressive international skills are valuable assets that will help us along our path, with developments set to accelerate in the coming months as our R&amp;D-focused Company begins its transition to a revenue-generating model, more in line with patients\u2019 needs. I\u2019m very happy to welcome him at what is a particularly exciting time for Valbiotis.<\/i>\u201d\n<\/p>\n<p>\nLaurent L\u00c9VY, Chairman of the Nanobiotix Executive Board and of the Valbiotis Supervisory Board, adds: <i>\u201cI speak on behalf of the entire Supervisory Board when I say that I\u2019m delighted with Fr\u00e9d\u00e9ric PELONG\u2019s appointment to the Valbiotis Board of Directors. His experience acquired working for large international groups and his in-depth operational and strategic knowledge of financial management will be decisive in spurring Valbiotis\u2019 growth.\u201d<\/i>\n<\/p>\n<p>\nAbout Valbiotis<br \/>\n<br \/>Valbiotis is a Research &amp; Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.<br \/>\n<br \/>Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.<br \/>\n<br \/>Its products are intended to be licensed to players in the health sector.<br \/>\n<br \/>Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France \u2013 P\u00e9rigny, La Rochelle (17) and Riom (63) \u2013 and a subsidiary in Quebec City (Canada).<br \/>\n<br \/>Valbiotis is a member of the &#8220;BPI Excellence&#8221; network and has been recognized as an &#8220;Innovative Company&#8221; by the BPI label. Valbiotis has also been awarded &#8220;Young Innovative Company&#8221; status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.<br \/>\n<br \/>For more information about Valbiotis, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.valbiotis.com&amp;esheet=52857500&amp;newsitemid=20220905005268&amp;lan=en-US&amp;anchor=www.valbiotis.com&amp;index=1&amp;md5=452c1772bc35963482e6cb5e08a54d45\" rel=\"nofollow noopener\" shape=\"rect\">www.valbiotis.com<\/a>\n<\/p>\n<p class=\"bwalignr\">\nName: Valbiotis<br \/>\n<br \/>ISIN Code: FR0013254851<br \/>\n<br \/>Ticker symbol: ALVAL<br \/>\n<br \/>EnterNext\u00a9 PEA-PME 150\n<\/p>\n<p>\nThis press release contains forward-looking statements about Valbiotis\u2019 objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022. This document is available on the Company\u2019s website (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.valbiotis.com%2F&amp;esheet=52857500&amp;newsitemid=20220905005268&amp;lan=en-US&amp;anchor=www.valbiotis.com&amp;index=2&amp;md5=6aa22f3d16147983e3cd56b883cf7d55\" rel=\"nofollow noopener\" shape=\"rect\">www.valbiotis.com<\/a>).<br \/>\n<br \/>This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis\u2019 shares or financial securities in any country.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nCorporate communication \/ Valbiotis<br \/>\n<br \/>Carole ROCHER<br \/>\n<br \/>Communication and Public Affairs Director<br \/>\n<br \/>+33 6 77 82 56 88\n<\/p>\n<p>\nMarc DELAUNAY<br \/>\n<br \/>Communication Manager<br \/>\n<br \/>+33 5 46 28 62 58<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#x3a;&#109;e&#x64;&#x69;&#x61;&#64;v&#x61;&#x6c;&#x62;&#105;o&#x74;&#x69;&#x73;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#101;d&#x69;&#97;&#64;&#x76;&#x61;&#108;&#x62;&#x69;&#111;t&#x69;&#115;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<p>\nFinancial communication \/ Actifin<br \/>\n<br \/>St\u00e9phane RUIZ<br \/>\n<br \/>Associate Director<br \/>\n<br \/>+33 1 56 88 11 14<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#111;&#58;&#115;&#114;uiz&#x40;&#x61;&#x63;&#x74;&#x69;&#x66;&#105;&#110;&#46;fr\" rel=\"nofollow noopener\" shape=\"rect\">&#115;&#x72;u&#105;&#x7a;&#64;&#97;&#x63;t&#x69;&#x66;&#105;&#x6e;&#46;&#102;&#x72;<\/a>\n<\/p>\n<p>\nMedia relations \/ PrPa<br \/>\n<br \/>Damien MAILLARD<br \/>\n<br \/>Operational Director<br \/>\n<br \/>+33 6 80 28 47 70<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x64;&#97;&#109;&#105;&#101;&#110;&#46;&#109;aill&#x61;&#x72;&#x64;&#x40;&#x70;&#x72;&#x70;&#x61;&#x2e;&#102;&#114;\" rel=\"nofollow noopener\" shape=\"rect\">damien&#46;m&#97;&#105;&#108;&#108;&#97;&#114;&#100;&#64;&#112;&#114;&#x70;&#x61;&#x2e;&#x66;&#x72;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Former Chief Financial Officer in numerous mid-caps and large international groups, with over 20 years\u2019 professional experience in France and abroad. The expertise necessary to accelerate Valbiotis\u2019 future hypergrowth in charge of the global financial strategy. A new appointment at a milestone in the Company\u2019s history, in preparation for commercialization. LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47986","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Former Chief Financial Officer in numerous mid-caps and large international groups, with over 20 years\u2019 professional experience in France and abroad. The expertise necessary to accelerate Valbiotis\u2019 future hypergrowth in charge of the global financial strategy. A new appointment at a milestone in the Company\u2019s history, in preparation for commercialization. LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T06:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors\",\"datePublished\":\"2022-09-06T06:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/\"},\"wordCount\":912,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220905005268\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/\",\"name\":\"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220905005268\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\",\"datePublished\":\"2022-09-06T06:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220905005268\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220905005268\\\/en\\\/1113003\\\/21\\\/LOGO-NOIR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors - Pharma Trend","og_description":"Former Chief Financial Officer in numerous mid-caps and large international groups, with over 20 years\u2019 professional experience in France and abroad. The expertise necessary to accelerate Valbiotis\u2019 future hypergrowth in charge of the global financial strategy. A new appointment at a milestone in the Company\u2019s history, in preparation for commercialization. LA ROCHELLE, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-06T06:01:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors","datePublished":"2022-09-06T06:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/"},"wordCount":912,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/","name":"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg","datePublished":"2022-09-06T06:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220905005268\/en\/1113003\/21\/LOGO-NOIR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/frederic-pelong-chief-financial-officer-joins-the-valbiotis-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Fr\u00e9d\u00e9ric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47986"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47986\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}